

Demerger of Hospitals Business of Fortis into Manipal

Significant Complementarity and Growth Benefits
To All Stakeholders









March 2018



Disclaimer

This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company.

Any reference in this presentation to "Fortis Healthcare Limited" shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction.

Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction.

This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

By attending this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.



Transaction Overview and Structure



FHL Hospitals Business and Manipal – A Snapshot

	Fortis Healthcare – Hospitals	Manipal Hospitals	Combined Entity
Overview	 Leading Indian integrated healthcare delivery service provider with 34 hospitals across India 	 South India's foremost multi-specialty healthcare provider with 11 hospitals spread across India and Malaysia 	 Leading integrated healthcare delivery service provider with Pan India presence
Geographic Presence	 India Presence: 31 hospitals in 15 cities across 10 states International Presence: Mauritius, Uganda and Sri Lanka 	 India Presence: 10 hospitals in 7 cities across 6 states International Presence: Malaysia (hospital) and Nigeria (clinic) 	 India Presence : 41 hospitals in 19 cities across 12 states International Presence : 5 countries
Specialities ⁽¹⁾	27% Renal Ortho Onco Others	14% - 7% - 4% - 8 Renal - Ortho - Onco - Others	24% 42% Renal Ortho 9% 11% Ohoco Others
Key Financials (TTM Dec'17)	Revenue: INR 3,727 crEBITDAC Margin: 13.5%EBITDA Margin: 6.4%	 Revenue: INR 1,503 cr EBITDA Margin: 16.0%⁽²⁾ 	Revenue: INR 5,230 cr BITDA Margin ⁽³⁾ : 14.2%
KPIs	 Hospitals: 34⁽⁴⁾ Bed capacity: 4,685⁽⁴⁾ Doctors: 2,650+ Nurses: 6,500+ Total Employees: 15,850+ 	 Hospitals: 11 Bed capacity: 2,973⁽⁵⁾ (additional 3,400+ beds in teaching hospitals) Doctors: 1,600+ (additional 1,300+ doctors in teaching hospitals) Nurses: 2,800+ Total Employees: 8,850+ 	 Hospitals: 45 Bed capacity: 7,658 Doctors: 4,200+ Nurses: 9,300+ Total Employees: 24,700+


Notes: (1) Revenue breakup for the nine month period ending 31st December 2017 excluding OPD; (2) Excludes one-off expense of INR 15 cr and loss from a operations of INR 27 cr from a newly commissioned hospital; (3) Includes c. INR 266 cr of BT costs eliminated on acquisition of RHT assets; (4) Includes 883 O&M beds across 8 hospitals (5 in India and 3 overseas); (5) Includes 850 installed capacity beds across 7 existing hospitals; (6) All financials throughout the presentation for Manipal Hospitals are unaudited management estimates

Why Manipal Hospitals?

- Strong brand with 65+ years legacy
- Backed by reputed promoter and global PE investors
- Well-recognised for safe and ethical medical practices



Well-recognised brand supported by marquee shareholders



Present across clinical specialties

Strong doctor connect

Manipal Hospitals LIFE'S ON

4th largest hospital chain

- Over 1,600+ doctors (and additional 1,300+ doctors in teaching hospitals)
- Captive medical college with over 400 doctors graduating each year and a strong alumni base



Strong historical financial performance with significant headroom for growth



- Witnessed Revenue CAGR of 20.5%⁽¹⁾ during FY12-FY17
- Recently invested significantly in greenfield and brownfield bed capacity to support future growth

Manipal Hospitals is one of India's foremost multi-specialty healthcare providers

Notes: (1) Historical revenue normalized for business reorganization and discontinued operations



Transaction Overview

The Board of Directors of Fortis Healthcare Limited ("FHL") at their meeting today: Approved the demerger of hospitals business of FHL ("F-HBU") into Manipal Hospitals Approved the sale of 20.0% stake in SRL to Manipal Hospitals for INR 720 Crs As part of the transaction, Dr. Ranjan Pai, promoter of Manipal Hospitals and TPG to invest c. INR 3,900 Crs into Manipal Hospitals to fund: Overview Acquisition of 50.9% stake in SRL (20.0% from FHL and 30.9% from other investors for which discussions are ongoing) Acquisition of RHT assets Key shareholders of the resultant entity will be Dr. Ranjan Pai and TPG Capital The ongoing demerger scheme for SRL will be withdrawn in due course **Swap Ratio** 10.83 shares of Manipal Hospitals for every 100 shares of FHL; Manipal Hospitals shares to be listed The key approvals required for the proposed transaction are: Shareholder approval⁽¹⁾ of FHL and Manipal Hospitals **Approvals** Securities and Exchange Board of India (SEBI); Stock Exchanges Competition Commission of India (CCI)

Target Completion Date


▶ The process is expected to be completed in approximately twelve months (Q4FY19)



National Company Law Tribunal (NCLT)

Proposed Transaction (1/2)

Demerger of F-HBU into Manipal Hospitals; Acquisition of 50.9% stake in SRL




- (I) F-HBU to demerge from FHL into Manipal Hospitals and shareholders of FHL to receive shares of Manipal Hospitals
- (II) Manipal Hospitals to acquire 50.9% stake in SRL (20.0% from FHL and 30.9% from other investors for which discussions are ongoing)

Note: (1) F-HBU includes all hospital business assets and liabilities of FHL



Proposed Transaction (2/2)

Resultant Structure:



- (I) Post the transaction, the shareholders of FHL will continue to hold shares in the resultant FHL (comprising 36.6% stake in SRL)
- (II) Additionally, for every 100 share held in FHL, 10.83 shares of Resultant Manipal Hospitals (comprising the entire hospitals business of FHL and Manipal Hospitals) will be issued

Note: (1) Adjusted for primary infusion of INR 3,900 cr in Manipal Hospitals by its Promoters and TPG Capital



Key Transaction Rationale




Combination likely to create significant value for all stakeholders and will provide a strong promoter and shareholder base to FHL's hospitals business and SRL



Leading healthcare company in the country (1/3)

Largest hospitals provider by Revenue and EBITDA





Creation of a leading healthcare platform with significant future growth potential




Best-in-class profitability

Source: Reported financials as per Company filings

Note: (1) Apollo hospital business revenue and EBITDA calculated as (consolidated EBITDA – standalone pharmacy business EBITDA); (2) Fortis EBITDAC before business trust costs; (3) Excludes one-off expense of INR 15 cr and loss from a operations of INR 22 cr from a newly commissioned hospital

Leading healthcare company in the country (2/3)

2nd largest by number of hospitals and operating beds





presence with meaningful scale in core markets




Complementary operational fit with enhanced service offerings

Source: Reported as per Company filings

Note: (1) Excludes 11 day care centers and 11 Cradles; (2) Includes 883 O&M beds across 8 hospitals (5 in India and 3 overseas); (3) 20 owned / operated hospitals (with P&L responsibility) in India, 3 managed hospitals and 1 hospital in Cayman Islands; (4) Includes 850 capacity beds across 7 existing hospitals

Leading healthcare company in the country (3/3)

Best in class operating metrics




Note: (1) Combined entity operating metrics calculated as weighted average operating metrics of individual companies (weighted by no of operating beds); (2) 9M FY18 numbers calculated as average of Q1, Q2 and Q3 of FY18




13

Benefits from complementary geographic footprint (1/2)




Benefits from complementary geographic footprint (2/2)



Well diversified pan-India presence with leading position in most markets



Strengthens presence in core markets - Bangalore





Post the combination, combined entity will have 9 hospitals with 1,600+ beds




Strategically located facilities with best-in-class complementary service offerings

Notes: (1) Numbers in brackets represent number of capacity beds



Strengthens presence in core markets - NCR





The combined entity will have 10 hospitals with c.1,900 beds in National Capital Region ("NCR")



Committed to treat patients with best-in-class service offerings

Notes: (1) Numbers in brackets represent number of capacity beds



Promotes excellence in healthcare practices (1/3)

Combined entity to have stronger presence across clinical specializations

					Strong Moderate Weak
Speciality	Fortis	•	Manipal		Merge Co
Cardiac		•		8	
Orthopaedics		•		⊖	
Nephrology / Urology		•			
Oncology		•		0	
Transplants		•		0	
Women & Child		•		8	
Critical Care		•		Θ	



Promotes excellence in healthcare practices (2/3)

Cutting edge medical technology and practices

Fortis

- 4 Da Vinci Robot
- 8 LINAC
- 32 Cath Labs

- 17 MRI
 - 21 CT Scanners
 - 6 PET CTs



Digital MRI



Brain Lab and Elekta



Bi-plane Cardiac Cath Lab



CT-based Brain Suite

Manipal

- 3 Da Vinci Robot
- ▶ 6 LINAC
- 11 Cath Labs

- 16 MRI
- 25 CT Scanners
- 2 PET CTs



Da vinci X Surgical Robotic Arm



Philip FD 20 Cath Lab + 3D EP



Cath Lab



EPIQ 7 C ECHO Cardiogrpahhy



Promotes excellence in healthcare practices (3/3)

Awards and Accreditations





✓ 4 JCI hospitals



✓ 19 NABH accredited Hospitals



9 hospitals



Manipal

5 Labs



Hospitals

✓ 8 hospitals



✓ 2 AAHRPP⁽¹⁾



√ 10 NABH accredited Blood Bank



2 NABH accredited Blood Bank



22 NABH Nursing Excellence



2 NABH Nursing Excellence

Note: (1) Association for the Accreditation of Human Research Protection Program



Offers significant synergy potential

Areas of synergies

Revenue Synergies

- Pan India presence
- Doctor retention
- Stronger brand equity
- Patient flow

Scale benefits

Leverage with credit customers

200-300bps higher revenue growth potential



Supply Chain Synergies

▶ Reduction in pharma, consumables and other expenses

SG&A / Shared Services Synergies

- Potential rationalization of general and administrative expenses
- Shared services and infrastructure

Opportunity for 150-250bps EBITDA margin expansion



Capex Synergies

- Scale to drive cost efficiency in capex related purchases
- Sharing of high end medical infrastructure in core markets



Accelerates growth potential

Significant recent investment to fuel near term growth



#


No. of beds

Significant capex incurred to build a strong pipeline of 1,500+ bed capacity



Integration plan to enable smooth transition


Companies to put together an 'empowered' integration team (after receiving requisite approvals) to preempt potential integration challenges






Proforma Shareholding Pattern


- Key shareholders of the resultant entity will be Dr. Ranjan Pai and TPG
 - As part of the proposed transaction, Dr. Ranjan Pai and TPG will invest c. INR 3,900 Crs as equity in the combined entity when demerger becomes effective











Adjusted for proposed investment of ~ INR 3,900 Crs

Notes: (1) As on 25th March 2018



Hospitals Proforma Financials

Key Parameters

key Parameters	L – HRO	ivianipai Hospitais	(Including RHT)
INR Crs; (TTM Dec'17)			
Revenue	3,727	1,503	5,230
EBITDAC	505	-	-
EBITDA	239	240 ⁽²⁾	745 ⁽³⁾
EBITDAC (%)	13.5%	-	-
EBITDA (%)	6.4%	16.0%	14.2%
Net Debt	1,311	1,266	3,563 ⁽⁴⁾
Operating Parameters			
No of Hospitals	34	11	45
No of Operational Beds	4,445	2,122	6,567
Capacity Beds	4,685	2,973	7,658
No of Patients ⁽⁵⁾	2,667,157	1,355,200	4,022,357
IPD ⁽⁵⁾	293,496	139,708	433,204
OPD ⁽⁵⁾	2,373,661	1,215,491	3,589,153

Combined Entity⁽¹⁾

Maninal Hospitals

Notes: (1) While the combined entity will consolidate SRL results, the financials presented here do not include SRL revenue of INR 845 Crs and EBITDA of INR 168 Crs for TTM Dec'17; (2) Excludes one-off expense of INR 15 cr and loss from a operations of INR 27 cr from a newly commissioned hospital; (3) Includes c. INR 266 cr of BT costs eliminated on acquisition of RHT assets; (4) Represents proforma calculation as of today adjusted for (a) debt of c. INR 2,600 Crs for acquisition assets of RHT Health Trust, (b) proceeds received from sale of SRL stake and (c) receipt of dividends from RHT; (5) 9M Dec'17 annualized

Transaction Process



Transaction Process

Obtaining in-principle approval for the proposed scheme from shareholders (*) CCI Filing and filing for approval from Stock Exchanges and SEBI **Demerger Process** Receipt of CCI and SEBI and stock exchanges approval **Estimated** Filing of Scheme with NCLT Completion ~ Q4 FY19 NCLT convened shareholder and creditor meet Receipt of scheme approval by NCLT Listing approval from Stock Exchanges Receipt of SGX Approval **RHT Process Estimated** Receipt of Unitholders Approval Completion ~ Q2 FY19 Completion of RHT acquisition



^{*} Upfront shareholder approval being taken voluntarily and is not required by law

Advisors to the Transaction

		Fortis Healthcare	Manipal – TPG
Fairness Opinion	•	Karvy Investor Services Limited	NA
Valuation Expert	•	Walker Chandiok & Co LLP	Walker Chandiok & Co LLP
Financial Advisors	•	Standard Chartered Bank	Allegro Capital, Goldman Sachs, Kotak Investment Banking
Legal Advisor	•	Cyril Amarchand Mangaldas	AZB Partners



Summary Takeaways









Creates the leading healthcare company in the country



Offers significant complementarity and growth potential



Cements leadership position in core markets



Brings together two strong cultures and employee best practices



Marquee shareholders for hospitals and diagnostics businesses



Provides capital for funding RHT acquisition



Appendix



Fortis Hospitals – Key hospitals 9MFY18

Fortis Escorts Heart Institute, Delhi



No of Operational Beds	294
Revenue (INR Cr)	289
ARPOB (INR Cr)	1.62
Occupancy	83%

Fortis Mulund, Mumbai



No of Operational Beds	292
Revenue (INR Cr)	230
ARPOB (INR Cr)	1.57
Occupancy	68%

Fortis Noida



No of Operational Beds	191
Revenue (INR Cr)	207
ARPOB (INR Cr)	1.84
Occupancy	82%

Fortis Hospital, BG Road, Bengaluru



No of Operational Beds	255
Revenue (INR Cr)	222
ARPOB (INR Cr)	1.56
Occupancy	75%

FMRI, Gurugram



No of Operational Beds	290
Revenue (INR Cr)	392
ARPOB (INR Cr)	2.81
Occupancy	66%

Fortis Mohali



No of Operational Beds	349
Revenue (INR Cr)	319
ARPOB (INR Cr)	1.65
Occupancy	75%



Manipal Hospitals - Key hospitals 9M FY18

Old Airport Rd, BLR



No of Capacity Beds	650
No of Operational Beds	614
Revenue (INR Cr)	547
ARPOB (INR Cr)	1.6
Occupancy	73%

KMC, Mangalore



No of Capacity Beds	410
No of Operational Beds	324
Revenue (INR Cr)	139
ARPOB (INR Cr)	0.8
Occupancy	68%

Klang, Malaysia



No of Capacity Beds	220
No of Operational Beds	127
Revenue (INR Cr)	98
ARPOB (INR Cr)	1.8
Occupancy	55%

Vijaywada



No of Capacity Beds	300
No of Operational Beds	241
Revenue (INR Cr)	74
ARPOB (INR Cr)	0.6
Occupancy	69%

Jaipur



No of Capacity Beds	202
No of Operational Beds	202
Revenue (INR Cr)	59
ARPOB (INR Cr)	0.8
Occupancy	46%


Goa



No of Capacity Beds	230
No of Operational Beds	121
Revenue (INR Cr)	51
ARPOB (INR Cr)	1.0
Occupancy	56%




Historical Financial Performance



Source: Company filings

Notes: (1) Historical Revenue and EBITDA are normalized for business reorganization and discontinued operations; (2) Excludes one-off expense of INR 15 cr and loss from operations of INR 27 cr from a Rewly commissioned hospital

Thank You



Fortis Healthcare Limited

March 2018

